The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial evaluating HER2 targeted activated T cells in advanced HER2 low expressing breast cancer patients.
Deepa Bai Jagtap
No relevant relationships to disclose
Archana Thakur
No relevant relationships to disclose
Abhinav Deol
No relevant relationships to disclose
Zaid Al-Kadhimi
No relevant relationships to disclose
Michael S. Simon
No relevant relationships to disclose
Lawrence E. Flaherty
No relevant relationships to disclose
Anthony Frank Shields
No relevant relationships to disclose
Dana Schalk
No relevant relationships to disclose
Elyse Paul
No relevant relationships to disclose
Vidya Kondadasula
No relevant relationships to disclose
Qin Liu
No relevant relationships to disclose
Lawrence G. Lum
Employment or Leadership Position - TransTarget (U)
Consultant or Advisory Role - TransTarget (U)
Stock Ownership - TransTarget
Research Funding - TransTarget Inc